Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs OTX-TKI (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Ocular Therapeutix
  • Most Recent Events

    • 09 Aug 2018 Status changed from planning to not yet recruiting.
    • 27 Apr 2018 According to an Ocular Therapeutix media release, company plans to initiate this trial in the second quarter of 2018.
    • 07 Nov 2017 According to an Ocular Therapeutix media release, Company expects to initiate this trial outside the United States for OTX-TKI in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top